Tue, Jul 22, 2014, 7:42 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

BioTime, Inc. Message Board

  • btimnextmicrosoft btimnextmicrosoft Jan 14, 2013 6:44 PM Flag

    Biotimes Heart Regen therapy by 2014

    The report demonstrates that the survival of human heart-derived cells is markedly improved when the cells are formulated in HyStem®-C, a product being developed by BioTime under the trade name ReneviaTM as a cell delivery device. In today’s publication, human heart-derived cells were transplanted into the hearts of mice around the time of injury in an animal heart attack model. When transplanted without matrix, the heart cells fared poorly, as is commonly observed in the absence of such support. However, when the cells were transplanted with HyStem®-C there was a significant increase in the number of surviving transplanted cells. Another significant finding reported in the study is that transplantation of the cells with HyStem®-C into the injured heart muscle resulted in an increase in left ventricular ejection fraction (LVEF), a measure of the ability of the cells to restore strength to the damaged heart wall. The lead author on the paper is Ke Cheng of the Cedars-Sinai Heart Institute in Los Angeles, California.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.78+0.13(+4.91%)Jul 22 4:01 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.